SoonerCare's three doors to a GLP-1

What changed, and what the document says

1. The heart door

   Not covered

   Wegovy is approvable for cardiovascular risk reduction, and the criteria close the obesity route in the next line.

   “Wegovy® will not be approved for obese or overweight members in the absence of established CVD; and”

   Oklahoma Health Care Authority (OHCA) — Prior Authorization (PA) 2026, Metabolic Disorders criteria — Aug 17, 2026

2. Who the heart door is open to

   Conditions apply

   A minimum age, a body mass index floor, and a documented cardiovascular event behind you.

   “Member must be 45 years of age or older; and”

   Oklahoma Health Care Authority (OHCA) — Prior Authorization (PA) 2026, Metabolic Disorders criteria — Aug 17, 2026

3. The liver door

   Not covered

   A second Wegovy criteria block exists for MASH, and it repeats the same exclusion in the same shape.

   “Wegovy® will not be approved for obese members in the absence of MASH; and”

   Oklahoma Health Care Authority (OHCA) — Prior Authorization (PA) 2026, Metabolic Disorders criteria — Aug 17, 2026

4. The sleep door

   Not covered

   Zepbound is reachable through moderate-to-severe sleep apnea, measured by a sleep study, and nothing else.

   “Zepbound® will not be approved for obese members in the absence of OSA; and”

   Oklahoma Health Care Authority (OHCA) — Prior Authorization (PA) 2026, Metabolic Disorders criteria — Aug 17, 2026

5. A separate authorization for every dose

   Conditions apply

   Titration is not covered by one approval. Each step up is its own request, approved eight weeks at a time.

   “Initial approvals will be for the titration period to allow initial and escalation dosing. A separate prior authorization request must be submitted for each dose; and”

   Oklahoma Health Care Authority (OHCA) — Prior Authorization (PA) 2026, Metabolic Disorders criteria — Aug 17, 2026

6. Titrate or stop

   Conditions apply

   A member who cannot climb to the maintenance dose loses the drug rather than staying on a lower one.

   “Members who cannot tolerate dose escalation to at least 5mg after an additional 8-week approval will not be approved for continuation; and”

   Oklahoma Health Care Authority (OHCA) — Prior Authorization (PA) 2026, Metabolic Disorders criteria — Aug 17, 2026

7. The diabetes ladder starts with metformin

   Conditions apply

   On the diabetes side the GLP-1s sit in a tier table, and no GLP-1 is in the first tier. Reaching the second one means three months of metformin first.

   “A trial at least 3 months in duration (unless intolerable adverse effects) of metformin titrated up to maximum dose, or a patient-specific, clinically significant reason why a 3-month trial of metformin titrated up to maximum tolerated dose is not appropriate must be provided.”

   Oklahoma Health Care Authority (OHCA) — Prior Authorization (PA) 2026, Diabetes/Endocrine criteria — Aug 10, 2026

8. Tirzepatide for diabetes has its own gate

   Conditions apply

   Mounjaro is not on the ladder at all. It sits in the special-authorization column, where the test is whether every cheaper GLP-1 has been ruled out in writing.

   “Member must be currently stabilized on the requested product (documentation must be provided) or a patient-specific, clinically significant reason (other than convenience) why the member cannot use all available lower-tiered GLP-1 or GIP/GLP-1 agonists must be provided; and”

   Oklahoma Health Care Authority (OHCA) — Prior Authorization (PA) 2026, Diabetes/Endocrine criteria — Aug 10, 2026

What the state didn't publish

No page in SoonerCare's published 2026 criteria approves a GLP-1 for obesity on its own. The two anti-obesity products appear on exactly one of the twenty-one category pages, and every block that names them rules out obesity without a second diagnosis.

We checked all 21 therapeutic-category criteria pages linked from SoonerCare's 2026 prior-authorization index, each fetched and read as text in a single pass.

Among the same 21 criteria pages, Wegovy appears 30 times and Zepbound 18 times on the Metabolic Disorders page, and neither appears on the other twenty pages. Victoza appears 10 times and Mounjaro and Ozempic twice each on the Diabetes/Endocrine page. The phrase Approval Criteria appears 2,573 times across the set. None of those 21 pages contains Saxenda or the phrase anti-obesity. The Metabolic Disorders page therefore matters: the diabetes page alone does not describe all of SoonerCare's GLP-1 criteria.

Source: Prior Authorization (PA) 2026, Oklahoma Health Care Authority (OHCA).

Which of these companies serve Oklahoma?

Of the 387 companies we grade, 34 publish a list of the states they are licensed in. We checked 251 more and found no such list on any page we read; 102 we have not checked either way.

22 of those lists name Oklahoma: Red Mountain Weight Loss, Gala Health, Care Bare Rx, Vita Bella, TelePeptide, Levity, Wisp, WePeptideRx, Ways2Well, TeleClinic, Tyde Wellness, Willow, VevaRx, Trimi, Enhance MD, HumeCare+, Rx.com, Mojoon, Peak Wellness, Sprout Health, Allara Health, and Mixx Health & Wellness. That is a licensure claim each company makes about itself, not something we checked with a state board.

A published list is a starting point, not a guarantee. If availability decides your choice, ask before you pay and get the answer in writing.

Coverage decides what you pay before cash does. See how state Medicaid programs cover GLP-1s and what a prior-authorization denial turns on.